Leukemia

概述 癌症中心临床科学部的历史可以追溯到癌症中心的早期。它始于达纳-法伯癌症研究所(DFCI)和波士顿儿童医院(CHB)的合作伙伴关系，后者成立于20世纪40年代末。DF/HCC联盟的形成导致了一个新的科学环境的发展，促进了临床研究人员之间以及与基础和人口同事之间的高度机构间合作。它还提供了接触更多患者的宝贵途径，以便在合理的时间框架内进行有希望的临床试验。其结果是形成了一个丰富而有凝聚力的科学社区，通过致力于转化性研究而统一起来，并由单一的临床研究结构提供支持。 组织 激励临床研究的基本组织单位仍然是临床计划。临床科学部包括十个以疾病为重点的项目(例如。前列腺癌)和支持转化性药理学和早期试验(TPETT)的项目。皮肤肿瘤学和黑色素瘤是这一应用中的一个新的临床程序。它在翻译发现方面有着出色的记录，强大的多机构 领导力、创新试验的良好记录、新的孢子和活跃的成员。

OVERVIEW The history of the Cancer Center's Clinical Science Division is rooted in the eariiest years of the Cancer Center. It began with the partnership of Dana-Farber Cancer Institute (DFCI) and Children's Hospital Boston (CHB), which was established in the late 1940s. The fomiation of the DF/HCC consortium has resulted in the development of a new scientific environment that fosters a high degree of inter-institutional collaboration among clinical investigators and with basic and population colleagues. It also has provided invaluable access to a far greater patient base so that promising clinical trials can be conducted in a reasonable timeframe. The result has been an enriched and cohesive scientific community unified through a commitment to translational research and supported by a single clinical tiials structure. Organization The basic organizing unit for stimulating clinical research remains the Clinical Programs. The Clinical Science Division includes ten programs that are disease-focused (e.g.. Prostate Cancer) and one that supports translational pharmacology and early phase trials (TPETT). Cutaneous Oncology and Melanoma is a new Clinical Program in this application. It has had an excellent record of translational discovery, strong multiinstitutional leadership, a favorable record of innovative trials, a renewed SPORE and active membership.